Aberrantly hypermethylated Homeobox A2 derepresses metalloproteinase-9 through TBP and promotes invasion in Nasopharyngeal carcinoma

Oncotarget

Volumn 4, Issue 11, 2013, Pages 2154-2165

  Li, Hsin Pai ^a   Peng, Chen Ching ^a   Chung, I Che ^a   Huang, Mei Yuan ^a   Huang, Shao Tung ^a   Chen, Chia Chun ^a   Chang, Kai Ping ^b   Hsu, Cheng Lung ^b   Chang, Yu Sun ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

DNA methylation; HOXA2; MMP9; NPC

Indexed keywords

E1A ASSOCIATED P300 PROTEIN; GELATINASE B; MESSENGER RNA; TATA BINDING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA2; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL CULTURE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; GENE DOSAGE; GENE SILENCING; HUMAN; HUMAN TISSUE; NASAL BIOPSY; NASOPHARYNX CARCINOMA; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; TUMOR INVASION; WESTERN BLOTTING;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA METHYLATION; GENES, HOMEOBOX; HOMEODOMAIN PROTEINS; HUMANS; MATRIX METALLOPROTEINASE 9; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; TATA-BOX BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION;

EID: 84890250237     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1367     Document Type: Article

References (42)

1. Wei WI and Sham JS. Nasopharyngeal carcinoma. Lancet. 2005; 365(9476):2041-2054.
2. Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C and Armand JP. Nasopharyngeal carcinomas: an update. European journal of cancer. 2003; 39(15):2121-2135.
3. Tse KP, Su WH, Chang KP, Tsang NM, Yu CJ, Tang P, See LC, Hsueh C, Yang ML, Hao SP, Li HY, Wang MH, Liao LP, Chen LC, Lin SR, Jorgensen TJ, et al. Genomewide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. American journal of human genetics. 2009; 85(2):194-203.
4. Thorley-Lawson DA and Allday MJ. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nature reviews Microbiology. 2008; 6(12):913-924.
5. Tsai CN, Tsai CL, Tse KP, Chang HY and Chang YS. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A. 2002; 99(15):10084-10089.
6. Tsai CL, Li HP, Lu YJ, Hsueh C, Liang Y, Chen CL, Tsao SW, Tse KP, Yu JS and Chang YS. Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)- terminal kinase signaling. Cancer Res. 2006; 66(24):11668-11676.
7. Esteller M. Epigenetics in cancer. N Engl J Med. 2008; 358(11):1148-1159.
8. Lopez-Serra L and Esteller M. Proteins that bind methylated DNA and human cancer: reading the wrong words. British journal of cancer. 2008; 98(12):1881-1885.
9. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nature reviews Genetics. 2012; 13(7):484-492.
10. Akin ZN and Nazarali AJ. Hox genes and their candidate downstream targets in the developing central nervous system. Cellular and molecular neurobiology. 2005; 25(3-4):697-741.
11. Lappin TR, Grier DG, Thompson A and Halliday HL. HOX genes: seductive science, mysterious mechanisms. Ulster Med J. 2006; 75(1):23-31.
12. Grier DG, Thompson A, Kwasniewska A, McGonigle GJ, Halliday HL and Lappin TR. The pathophysiology of HOX genes and their role in cancer. The Journal of pathology. 2005; 205(2):154-171.
13. Kutejova E, Engist B, Self M, Oliver G, Kirilenko P and Bobola N. Six2 functions redundantly immediately downstream of Hoxa2. Development. 2008; 135(8):1463-1470.
14. Lampe X, Picard JJ and Rezsohazy R. The Hoxa2 enhancer 2 contains a critical Hoxa2 responsive regulatory element. Biochem Biophys Res Commun. 2004; 316(3):898-902.
15. Li LC and Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002; 18(11):1427-1431.
16. Hsieh CL. Stability of patch methylation and its impact in regions of transcriptional initiation and elongation. Molecular and cellular biology. 1997; 17(10):5897-5904.
17. Chan HM and La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. Journal of cell science. 2001; 114(Pt 13):2363-2373.
18. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000; 18(5):1135-1149.
19. Tang JG, Li X and Chen P. Expression of matrix metalloproteinase 9 in nasopharyngeal carcinoma and association with Epstein-Barr virus infection. J Zhejiang Univ Sci. 2004; 5(10):1304-1312.
20. Takeshita H, Yoshizaki T, Miller WE, Sato H, Furukawa M, Pagano JS and Raab-Traub N. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol. 1999; 73(7):5548-5555.
21. Lee DC, Chua DT, Wei WI, Sham JS and Lau AS. Induction of matrix metalloproteinases by Epstein-Barr virus latent membrane protein 1 isolated from nasopharyngeal carcinoma. Biomed Pharmacother. 2007; 61(9):520-526.
22. Smith TM, Wang X, Zhang W, Kulyk W and Nazarali AJ. Hoxa2 plays a direct role in murine palate development. Dev Dyn. 2009; 238(9):2364-2373.
23. Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P and Yu D. Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene. 2001; 20(56):8066-8074.
24. Kirilenko P, He G, Mankoo BS, Mallo M, Jones R and Bobola N. Transient activation of meox1 is an early component of the gene regulatory network downstream of hoxa2. Molecular and cellular biology. 2011; 31(6):1301-1308.
25. Kutejova E, Engist B, Mallo M, Kanzler B and Bobola N. Hoxa2 downregulates Six2 in the neural crest-derived mesenchyme. Development. 2005; 132(3):469-478.
26. Schwarzenbach H, Chun FK, Isbarn H, Huland H and Pantel K. Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients. Journal of cancer research and clinical oncology. 2011; 137(5):811-819.
27. Davenne M, Maconochie MK, Neun R, Pattyn A, Chambon P, Krumlauf R and Rijli FM. Hoxa2 and Hoxb2 control dorsoventral patterns of neuronal development in the rostral hindbrain. Neuron. 1999; 22(4):677-691.
28. Ohnemus S, Bobola N, Kanzler B and Mallo M. Different levels of Hoxa2 are required for particular developmental processes. Mechanisms of development. 2001; 108(1-2):135-147.
29. Zappavigna V, Sartori D and Mavilio F. Specificity of HOX protein function depends on DNA-protein and proteinprotein interactions, both mediated by the homeo domain. Genes & development. 1994; 8(6):732-744.
30. Cillo C, Faiella A, Cantile M and Boncinelli E. Homeobox genes and cancer. Exp Cell Res. 1999; 248(1):1-9.
31. Makiyama K, Hamada J, Takada M, Murakawa K, Takahashi Y, Tada M, Tamoto E, Shindo G, Matsunaga A, Teramoto K, Komuro K, Kondo S, Katoh H, Koike T and Moriuchi T. Aberrant expression of HOX genes in human invasive breast carcinoma. Oncol Rep. 2005; 13(4):673-679.
32. Shiraishi M, Sekiguchi A, Oates AJ, Terry MJ and Miyamoto Y. HOX gene clusters are hotspots of de novo methylation in CpG islands of human lung adenocarcinomas. Oncogene. 2002; 21(22):3659-3662.
33. Imanishi Y, Fujii M, Tokumaru Y, Tomita T, Kanke M, Kanzaki J, Kameyama K, Otani Y and Sato H. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma. Hum Pathol. 2000; 31(8):895-904.
34. Yoshizaki T, Sato H, Furukawa M and Pagano JS. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95(7):3621-3626.
35. Yoshizaki T, Sato H, Murono S, Pagano JS and Furukawa M. Matrix metalloproteinase 9 is induced by the Epstein- Barr virus BZLF1 transactivator. Clinical & experimental metastasis. 1999; 17(5):431-436.
36. Liu Z, Li L, Yang Z, Luo W, Li X, Yang H, Yao K, Wu B and Fang W. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer. 2010; 10:270.
37. Hsu CL, Chang KP, Lin CY, Chang HK, Wang CH, Lin TL, Liao CT, Tsang NM, Lee LY, Chan SC, Ng SH, Li HP, Chang YS and Wang HM. Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. Head & neck. 2012; 34(8):1064-1070.
38. Yang C, Bolotin E, Jiang T, Sladek FM and Martinez E. Prevalence of the initiator over the TATA box in human and yeast genes and identification of DNA motifs enriched in human TATA-less core promoters. Gene. 2007; 389(1):52-65.
39. Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, Tsang YS, Wong N, Whitney BM and Lee JC. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer. 1999; 83(1):121-126.
40. Huang DP, Ho JH, Poon YF, Chew EC, Saw D, Lui M, Li CL, Mak LS, Lai SH and Lau WH. Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx. Int J Cancer. 1980; 26(2):127-132.
41. Ehrich M, Turner J, Gibbs P, Lipton L, Giovanneti M, Cantor C and van den Boom D. Cytosine methylation profiling of cancer cell lines. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(12):4844-4849.
42. Chen LC, Chung IC, Hsueh C, Tsang NM, Chi LM, Liang Y, Chen CC, Wang LJ and Chang YS. The antiapoptotic protein, FLIP, is regulated by heterogeneous nuclear ribonucleoprotein K and correlates with poor overall survival of nasopharyngeal carcinoma patients. Cell death and differentiation. 2010; 17(9):1463-1473.